Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
OPHT's Cash to Debt is ranked higher than
71% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. OPHT: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OPHT' s 10-Year Cash to Debt Range
Min: 0.4  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.29
OPHT's Equity to Asset is ranked lower than
85% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. OPHT: 0.29 )
Ranked among companies with meaningful Equity to Asset only.
OPHT' s 10-Year Equity to Asset Range
Min: 0.27  Med: 0.29 Max: 0.36
Current: 0.29
0.27
0.36
Interest Coverage No Debt
OPHT's Interest Coverage is ranked lower than
64% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPHT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OPHT' s 10-Year Interest Coverage Range
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
Z-Score: 3.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -63.00
OPHT's Operating margin (%) is ranked higher than
51% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. OPHT: -63.00 )
Ranked among companies with meaningful Operating margin (%) only.
OPHT' s 10-Year Operating margin (%) Range
Min: -195.14  Med: -195.14 Max: -195.14
Current: -63
Net-margin (%) -107.86
OPHT's Net-margin (%) is ranked lower than
54% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. OPHT: -107.86 )
Ranked among companies with meaningful Net-margin (%) only.
OPHT' s 10-Year Net-margin (%) Range
Min: -283.02  Med: -283.02 Max: -283.02
Current: -107.86
ROE (%) -55.01
OPHT's ROE (%) is ranked lower than
59% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. OPHT: -55.01 )
Ranked among companies with meaningful ROE (%) only.
OPHT' s 10-Year ROE (%) Range
Min: -246.64  Med: -162.47 Max: -78.3
Current: -55.01
-246.64
-78.3
ROA (%) -19.93
OPHT's ROA (%) is ranked higher than
59% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. OPHT: -19.93 )
Ranked among companies with meaningful ROA (%) only.
OPHT' s 10-Year ROA (%) Range
Min: -231.01  Med: -45.96 Max: -33.48
Current: -19.93
-231.01
-33.48
ROC (Joel Greenblatt) (%) -350.57
OPHT's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. OPHT: -350.57 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPHT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -65147.62  Med: -16410.03 Max: -7700.91
Current: -350.57
-65147.62
-7700.91
» OPHT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

OPHT Guru Trades in Q3 2013

Columbia Wanger 264,000 sh (New)
» More
Q4 2013

OPHT Guru Trades in Q4 2013

Columbia Wanger Sold Out
» More
Q4 2014

OPHT Guru Trades in Q4 2014

Jim Simons 16,300 sh (New)
» More
Q1 2015

OPHT Guru Trades in Q1 2015

Jim Simons 389,200 sh (+2287.73%)
» More
» Details

Insider Trades

Latest Guru Trades with OPHT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 48.31
OPHT's Forward P/E is ranked lower than
75% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. OPHT: 48.31 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 16.13
OPHT's P/B is ranked lower than
86% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. OPHT: 16.13 )
Ranked among companies with meaningful P/B only.
OPHT' s 10-Year P/B Range
Min: 7.09  Med: 12.12 Max: 16.85
Current: 16.13
7.09
16.85
P/S 27.45
OPHT's P/S is ranked lower than
71% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. OPHT: 27.45 )
Ranked among companies with meaningful P/S only.
OPHT' s 10-Year P/S Range
Min: 19.4  Med: 32.95 Max: 47.27
Current: 27.45
19.4
47.27
PFCF 22.78
OPHT's PFCF is ranked higher than
73% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. OPHT: 22.78 )
Ranked among companies with meaningful PFCF only.
OPHT' s 10-Year PFCF Range
Min: 12.36  Med: 16.10 Max: 23.79
Current: 22.78
12.36
23.79
POCF 22.47
OPHT's POCF is ranked higher than
70% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. OPHT: 22.47 )
Ranked among companies with meaningful POCF only.
OPHT' s 10-Year POCF Range
Min: 13.33  Med: 16.91 Max: 23.47
Current: 22.47
13.33
23.47
EV-to-EBIT -34.39
OPHT's EV-to-EBIT is ranked lower than
475% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. OPHT: -34.39 )
Ranked among companies with meaningful EV-to-EBIT only.
OPHT' s 10-Year EV-to-EBIT Range
Min: -38.9  Med: -17.65 Max: -12.7
Current: -34.39
-38.9
-12.7
Current Ratio 24.03
OPHT's Current Ratio is ranked higher than
93% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. OPHT: 24.03 )
Ranked among companies with meaningful Current Ratio only.
OPHT' s 10-Year Current Ratio Range
Min: 0.34  Med: 23.87 Max: 40.94
Current: 24.03
0.34
40.94
Quick Ratio 24.03
OPHT's Quick Ratio is ranked higher than
94% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. OPHT: 24.03 )
Ranked among companies with meaningful Quick Ratio only.
OPHT' s 10-Year Quick Ratio Range
Min: 0.34  Med: 23.87 Max: 40.94
Current: 24.03
0.34
40.94
Days Sales Outstanding 221.14
OPHT's Days Sales Outstanding is ranked lower than
91% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. OPHT: 221.14 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPHT' s 10-Year Days Sales Outstanding Range
Min: 8.49  Med: 8.49 Max: 8.49
Current: 221.14

Valuation & Return

vs
industry
vs
history
Price/Net Cash 30.03
OPHT's Price/Net Cash is ranked lower than
83% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. OPHT: 30.03 )
Ranked among companies with meaningful Price/Net Cash only.
OPHT' s 10-Year Price/Net Cash Range
Min: 4.8  Med: 11.95 Max: 20.87
Current: 30.03
4.8
20.87
Price/Net Current Asset Value 16.91
OPHT's Price/Net Current Asset Value is ranked lower than
74% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. OPHT: 16.91 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OPHT' s 10-Year Price/Net Current Asset Value Range
Min: 4.74  Med: 8.81 Max: 12.36
Current: 16.91
4.74
12.36
Price/Tangible Book 16.13
OPHT's Price/Tangible Book is ranked lower than
80% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. OPHT: 16.13 )
Ranked among companies with meaningful Price/Tangible Book only.
OPHT' s 10-Year Price/Tangible Book Range
Min: 4.74  Med: 7.42 Max: 11.75
Current: 16.13
4.74
11.75
Price/Median PS Value 0.86
OPHT's Price/Median PS Value is ranked higher than
70% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. OPHT: 0.86 )
Ranked among companies with meaningful Price/Median PS Value only.
OPHT' s 10-Year Price/Median PS Value Range
Min: 0.6  Med: 1.04 Max: 1.14
Current: 0.86
0.6
1.14
Earnings Yield (Greenblatt) (%) -2.90
OPHT's Earnings Yield (Greenblatt) (%) is ranked higher than
61% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. OPHT: -2.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPHT' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -7.5  Med: 0.00 Max: 0
Current: -2.9
-7.5
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:O2T.Germany,
» More Articles for OPHT

Headlines

Articles On GuruFocus.com
Can These Three BioTech Companies Make It Big? Feb 20 2015 
Weekly 3-Year Low Highlight: VIV, CNHI, WTW, OPHT Nov 17 2013 
Insiders Are Buying Ophthotech Oct 08 2013 

More From Other Websites
Ophthotech Corporation to Report Second Quarter 2015 Financial Results and Host Conference Call on... Jul 29 2015
Ophthotech Corporation to Report Second Quarter 2015 Financial Results and Host Conference Call on... Jul 29 2015
Will Ophthotech (OPHT) Continue to Surge Higher? - Tale of the Tape Jul 29 2015
OPHTHOTECH CORP. Files SEC form 8-K, Results of Operations and Financial Condition, Non-Reliance on... Jul 28 2015
OPHTHOTECH CORP. Files SEC form 8-K, Change in Directors or Principal Officers Jul 21 2015
Ophthotech Announces New Senior Leadership Appointments Jul 21 2015
Ophthotech Announces New Senior Leadership Appointments Jul 21 2015
Ophthotech (OPHT) is Overbought: Is A Drop Coming? - Tale of the Tape Jul 21 2015
Trending Now: Ophthotechn Jul 17 2015
Street Talk: OPHT under the radar Jul 07 2015
Coverage initiated on Ophthotech by Cowen Jul 07 2015
OPHTHOTECH CORP. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jun 04 2015
Ophthotech Corporation to Present at the Goldman Sachs 36th Annual Global Healthcare Conference Jun 03 2015
Ophthotech Corporation to Present at the Goldman Sachs 36th Annual Global Healthcare Conference Jun 03 2015
OPHTHOTECH CORP. Financials May 20 2015
Ophthotech Corporation to Present at the UBS Global Healthcare Conference May 13 2015
Ophthotech Corporation to Present at the UBS Global Healthcare Conference May 13 2015
Small-Cap Biotech Stocks to Watch May 12 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK